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Abstract  
Pediatric follicular lymphoma is a rare disease that differs genetically and clinically from 
its adult counterpart. With the exception of pediatric follicular lymphoma with IRF4-
translocation, the genetic events associated with these lymphomas have not yet been 
defined. We applied array-comparative genomic hybridization and molecular inversion 
probe assay analyses to formalin-fixed paraffin-embedded tissues from 18 patients 
aged ≤18 years with IRF4 translocation negative follicular lymphoma. All evaluable 
cases lacked t(14;18). Only six of 16 evaluable cases displayed chromosomal 
imbalances with gains or amplifications of 6pter-p24.3 (including IRF4) and deletion 
and copy number neutral-loss of heterozygosity in 1p36 (including TNFRSF14) being 
most frequent. Sequencing of TNFRSF14 located in the minimal region of loss in 
1p36.32 showed nine mutations in seven cases from our series. Two subsets of 
pediatric follicular lymphoma were delineated according to the presence of molecular 
alterations, one with genomic aberrations associated with higher grade and/or diffuse-
large-B-cell lymphoma component and more widespread disease, and another one 
lacking genetic alterations associated with more limited disease.  
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Introduction  
Follicular Lymphoma (FL) is the most frequent indolent lymphoma in the Western 
World and accounts for about 20-40% of all B-cell lymphomas.1 Pediatric FL are 
considered as variant of FL that differ from adult FL with an increased proportion 
exhibiting high grade histology and most cases presenting clinically as localized and 
curable diseases.2-4 Moreover, pediatric FL differ genetically from their adult 
counterpart.2 The genetic hallmark of adult FL, the translocation t(14;18)(q32;q21) 
affecting the BCL2 gene is hardly ever present in pediatric FL.2,3 Overall and in 
contrast to adult FL, the genetic events associated with pediatric FL pathogenesis and 
prognosis have not yet been defined, with the notable exception of those pediatric 
cases carrying an IRF4 translocation.4 Thus, we have here applied array-comparative 
genomic hybridization (aCGH) and molecular inversion probe (MIP) assay adapted for 
formalin-fixed, paraffin-embedded (FFPE) tissues to FL of 18 patients diagnosed up to 
the age of 18 years.  
 
Methods  
The study included 18 pediatric FL lacking an IRF4 translocation with available FFPE 
tissue diagnosed in patients aged up to 18 years; ten cases were previously reported 
with regard to clinicopathological features.3 With the exception of one case with only 
focal involvement by lymphoma (pFL13), the tumor cell content exceeded 50% in the 
evaluable samples. Eleven of 18 patients were treated according to NHL-BFM group 
multicenter trials,5,6 whereas the remaining according to different treatment strategies. 
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Clinical and histopathologic data are summarized in supplemental material and 
Supplementary Table 1. 
DNA was extracted from FFPE tissue blocks using a phenol-chloroform extraction 
method.7 Fourteen cases were hybridized on the MIP-assay using Oncoscan FFPE 
Express custom service (Affymetrix, Santa Clara, CA).8 Thirteen cases were analyzed 
using Agilent 244K array (Agilent Technologies, Santa Clara, CA), including nine 
cases simultaneously analyzed by MIP-assay (Supplementary information and 
Supplementary Figure 1). Copy number (CN) plots were generated by the use of 
Nexus 6.0 beta Discovery Edition software (Biodiscovery, El Segundo, CA). Gains and 
losses were evaluated by two different observers.  
Fluorescence in situ hybridization (FISH) analyses were performed for the detection of 
breakpoints or gene fusions and for verification of gains in chromosome 6p25 as 
previously described.9,10 For this purpose commercially available MYC BAP, BCL2 
BAP, IGH BAP and BCL6 BAP probes, an IGH/BCL2 double-color double-fusion probe 
(all Abbott/Vysis, Downers Grove, IL) and a previously designed FISH probe for IRF4 
(BAP)4 were used. 
Potential point mutations detected by MIP-assay in PIK3CA, FBXW7, ABL1, NOTCH1, 
STK11 and PTEN were also analyzed by direct sequencing using ABI PRISM 3100 
Genetic Analyzer system (Applied Biosystems, Foster City, CA). Details are described 
in the supplementary files. Similarly, the coding exons of TNFRSF14 (Supplementary 
Table 2) and Tyr641 EZH24 were also analyzed by direct sequencing in the whole 
series.  
Clonality analysis was performed investigating the framework 1-3 regions of the 
immunoglobulin heavy chain (IGH) according to the Biomed-2 protocol.11  
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Statistical analyses were performed using PASW Statistics software version 18 (SPSS 
Inc., Chicago, IL).  
The study was performed in the framework of the BFM-NHL trial, for which central and 
local institutional review board approvals were obtained and according to the guidelines 
of the MMML Network Project of the Deutsche Krebshilfe (approved by the Institutional 
Review Board (IRB) of the Medical Faculty Kiel under 403/05). 
 
Results and Discussion 
Pediatric FL is a rare disease that differs from its adult counterpart both genetically and 
clinically.3 We recently described a distinct subset of germinal center B-cell lymphomas 
including FL characterized by the presence of IRF4 gene translocations, predominately 
affecting children and young adults.4 In the present study, we determined genetic 
aberrations in a series of 18 pediatric FL cases lacking such IRF4 translocation. Of 
these 18 FL, nine (50%) were classified as FL grade 3a (FL3a), six (33%) as grade 3b 
(FL3b), one (6%) as grade 3 unclassified and two (11%) as grade 2. Areas of grade 1 
or 2 FL as a second lymphoma component were detectable in four cases diagnosed 
as FL3a (22%), while a simultaneous diffuse large B-cell lymphoma (DLBCL) 
component was noted in four (22%) cases, three diagnosed as FL3b and one as FL3a. 
Seven patients presented with stage I disease, five were rated as stage II and three 
suffered from stage III disease. Tumor localization in or dissemination to neck region 
was the most frequent presentation (11 of 18). Notably, the present series of pediatric 
FL seems to differ from those of other recently published series with regard to sites of 
involvement, clinical stage and presence of a DLBCL component.12,13 This might be 
due to the fact that the present series predominately reflects population-based 
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ascertainment for a pediatric clinical trial rather than collections at consultation centers. 
The patients were predominantly male (61%), with a median age of 12.1 years (range, 
6-18 years). All cases evaluable for the respective analyses lacked BCL2 breakpoints 
and/or IGH-BCL2 fusion and MYC breakpoints by FISH. Breaks in IGH locus occurred 
in four of 15 evaluable cases whereas a BCL6 break occurred in one of 17 cases 
(Supplementary Table 1). 
CN determination by aCGH and/or MIP-assay was successful in 16 of the 18 FL (89%) 
(Supplementary Figure 1). Eight samples were analyzed on both CN platforms showing 
a good agreement (with seven showing the same imbalances by both platforms). Only 
one case (pFL12) with low quality DNA showed differences between platforms, with a 
chromosome 7 gain only detectable using MIP-assay. Only six of 16 evaluable 
pediatric FL (37%) displayed CN alterations and/or copy number neutral-loss of 
heterozygosity (CNN-LOH), with a mean of 6.5 aberrations per case (Figure 1A and 
Supplementary Tables 3 and 4). These findings contrast with adult FL, where the 
number of cases with chromosomal imbalances14 and CNN-LOH15 is higher (71.6% vs. 
37.5%, P-value=0.01 and 76% vs. 40%, P-value=0.05, respectively). The most 
frequent imbalance in pediatric FL was 6pter-p24.3 gain including amplification (3/6 
aberrant cases). Despite IRF4 was shown by FISH to be included in the gained region 
(Supplementary Figure 2), no consistent expression of IRF4/MUM1 was observed in 
these cases (2/3 expressed IRF4/MUM1). Remarkably, three cases showed CNN-LOH 
in 1p36.32-p36.13 region (pFL7, pFL8, and pFL14) (Figure 1B) and another one 
showed a deletion of the whole 1p arm (pFL5). In comparison with three previously 
published pediatric FL positive for IRF4 translocation,16 cases positive for the 
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translocation were significantly more complex in terms of CN alterations than the IRF4 
negative pediatric FL (7 alterations/case vs. 2.4 alterations/case p=0.029) 
(Supplementary Figure 3). Of note, IRF4 translocation positive cases presented more 
frequently gains of 11q and deletions of 17p arm including TP53 gene. Furthermore, 
one of the cases showed a deletion at 1pter-p35.2 with a transition mutation in the 
TNFRSF14 gene (g.343C>T, T15I) (data not shown). 
Both the gain in 6p as well as CNN-LOH/loss of 1p seem to be not exclusive to 
pediatric FL, since they have been also described in adult FL independently of the 
presence of t(14;18) translocation.14 In fact, deletions and CNN-LOH of 1p36 have 
been described as one of the most frequent secondary genetic aberrations in adult 
FL15 and are considered a significant predictor of poor overall survival.17 The minimal 
region of loss/CNN-LOH in 1p36 contains the candidate gene TNFRSF14, encoding a 
member of the tumor necrosis factor receptor (TNFR) superfamily, which has been 
shown to be recurrently mutated in adult FL.18,19 Sequencing of TNFRSF14 in the four 
pediatric FL with 1p36 aberration revealed three to carry mutations, including one 
missense mutation in exon 1 (g.340C>G, S14C; pFL7), two splice donor site mutations 
of the exon 1 (g.370T>C and g.370T>A; pFL7 and pFL10) and one nonsense mutation 
in exon 5 (g.4336C>T, Q180X; pFL14). Extension of the TNFRSF14 mutation 
screening to the rest of the cases revealed five non-synonymous mutations in four 
pediatric FL without 1p36 aberration (Supplementary Table S5). Thus, 7/17 pediatric 
FL contain mutations in TNFRSF14 rendering this the most recurrent change in this 
disease hitherto known. In order to identify the incidence of previously described EZH2 
DOI: 10.3324/haematol.2012.073916
 8
protein mutation (Tyr641),20 the whole series of pediatric FL was sequenced, finding 
two cases mutated (pFL3 and pFL15) (Supplementary Table 3).  
A synopsis of the obtained molecular profiling results revealed that all cases with 
breaks in IGH or BCL6 also showed CN alterations and/or mutations in TNFRSF14 or 
EZH2 genes. Based on the results of the molecular analyses, two groups of FL could 
be distinguished: one containing the genetically aberrant pediatric FL and another one 
comprising the pediatric FL without any aberration (Figure 1C). The absence of 
genomic aberrations due to a low content of tumor cells was ruled out in all the 
patients (>50% tumor cell content) except in case pFL13 (20%). Nevertheless, we 
cannot rule out the percentage of (sub)clonal cells harboring a genetic aberration 
might influence the grouping.  
Studying IGH clonality revealed that the two samples with polyclonal pattern (pFL2 and 
pFL11) were in the set lacking genomic aberrations. In one of the cases (pFL2) only 
the FR3 region was evaluable in the central IGH clonality analysis. Therefore, we 
cannot exclude that clonality could be detectable with FR1 or FR2 primers. Despite the 
polyclonal pattern, both cases displayed clear histomorphological features of 
malignancy with subtotal effacement of the underlying lymphnode structure, 
destruction of the normal germinal center architecture, loss of follicle mantles and 
abnormality enlarged in part confluent neoplastic follicles. Although there is general 
agreement regarding the absence of BCL2-rearrangement in pediatric FL at the 
molecular level, reported levels of BCL2 protein expression vary considerably ranging 
from 0% to 50%.2,3,12,13 In our series, the majority of the cases (12/15) expressed the 
protein to some degree. The relatively high proportion of BCL2 expressing cases in our 
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series, in comparison to previous reports, might be due to the selection criteria applied, 
like including cases of FL with simultaneous DLBCL component and excluding cases 
with IRF4 translocations. No correlation was found between BCL2 expression and the 
presence of genetic aberrations.  
Comparing the two groups defined by the genomic aberration status with clinical data, 
the group with aberrations was enriched for patients showing higher grade histology 
and higher stage disease patterns. E.g. advanced disease stage (>II), grade 3b or a 
DLBCL component occurred almost exclusively in the genetically altered group (Table 
1). In contrast, lack of genetic aberrations occurred in clinical stages (I and II) and was 
never associated with a DLBCL component, although this was not statistically 
significant probably because of the low number of cases (Figure 1C). Notably, 
comparing cases with and without neck region tumor localization/involvement, the 
second group was significantly associated with the presence of genomic aberrations 
(P=0.03). Previous studies have shown that tonsillar pediatric FL are nearly always 
positive for MUM1/IRF4.13 Nevertheless, the present series shows few cases (pFL4 
and pFL 15) with tonsillar involvement, which at least in part is likely due to exclusion of 
the cases harboring IRF4 translocations known to be strongly MUM1 positive.4 
Despite these biologic differences, the overall survival was comparable between the 
groups with genomic aberrations and without them (Table 1 and Supplementary Table 
1). This might be associated with the fact that most patients (12/16) besides the 
diagnostic lymph node excision received treatment with multi-agent chemotherapy. The 
whole series showed an excellent survival with all patients being alive at the last follow-
up, independently of the biologic subgrouping, with a median follow up of 60.6 months. 
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In summary, we describe the pattern of genomic imbalances in IRF4 translocation 
negative pediatric FL and identify recurrent mutation of TNFRSF14. Moreover, we 
show genetic alterations to distinguish two subsets of pediatric FL: in the first subset 
genomic aberrations could be identified with the techniques applied and this subset is 
associated with higher grade and/or diffuse-large-B-cell lymphoma component and 
more widespread disease. The second group lacks genetic alterations detectable with 
the present approaches and is associated with a more limited disease. Despite the 
absence of genomic aberrations, these cases resembled FL by their histopathological 
features (Figure 2). The absence of genetic aberrations detectable with the methods 
used in the current study does not necessarily mean that these lesions are completely 
devoid of genomic aberrations. Since the histopathology of these lesions is not 
compatible with reactive conditions, it seems possible that a higher resolution of 
genomic analysis like next generation sequencing will reveal aberrations. In turn, the 
presence of genetic aberrations does not ultimately proof malignancy as documented 
e.g. in monoclonal gammopathy of undetermined significance (MGUS).1 Indeed, it 
could well be that at least a subset of pediatric FL could similarly represent monoclonal 
follicular proliferations of undetermined significance. 
Given that the patients included in this study have been treated independently of the 
genomic aberration status and show an excellent survival, thus we cannot comment on 
whether the detectability or pattern of genomic differences also translate into a 
different clinical outcome and whether the genetically normal appearing FL might be 
treated less intensively or can even be simply watched in completely resected local 
disease.  
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Table 1. Comparison of clinical and biological characteristics of pediatric follicular lymphoma 
(FL) with genomic aberrations versus pediatric FL without aberrations 
 
Clinical and biological 
characteristics  
Ped FL with  
genomic aberrations  
Ped FL without 
genomic aberrations  P-value  
Gender ratio (M:F)  1.2:1  2.5:1  0.64  
Age (median)  12.1  12 0.97  
Grade FL 
      
1-2 1 1 
0.31 
3a 4a 5b 
3b 5 1 
grade 3 unknown 1 - 
Stage 
      
I 2 5 
0.11 
II 3 2 
III 3 0 
nd  3 - 
DLBCL component  
      
No 7 7 
0.12 
Yes  4c 0 
Localization        
Neck region  4 7  
0.03 Other regions  4 0 
Both  3 0 
Remnants of reactive B-follicles 
    
  
0.38 
No 5 2 
Yes 5 5 
nd 1 - 
Marginal zone differentiation 
      
No 9 4 
0.33 
Yes 2 3 
Ki67 (%) 55d 54e 0.99 
Tumor cell content (%)  76.4 67.9 0.32  
Median follow-up (months)  73.8e 43.6 0.21 
 
nd, not determined; DLBCL; diffuse large B-cell Lymphoma; M, male; F, female 
aOne case with FL1/2 as a second lymphoma component 
bThree cases with FL1/2 as a second lymphoma component 
cCase pFL8 present starry sky pattern- Burkitt like pattern 
dData not available in one case  
eData not available in two cases 
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Figure legend 
Figure 1. (A) Copy number (CN) profiles of 16 pediatric FL. In the X-axis the 
chromosomes are represented horizontally from 1 to 22, in the Y-axis the percentage 
of cases showing the CN alterations. Gains are represented in the positive Y-axis and 
colored in yellow, whereas losses are represented in the negative Y-axis in blue. The 
most frequent CN alteration was gain/amplification of 6pter-p24.3. (B) Molecular 
Inverse Probe (MIP)-assay profiles showing CN neutral loss of heterozygosity (CNN-
LOH) at 1p36 in the pFL7, pFL10 and pFL14 cases. Allelic events are displayed along 
the X axis (from pter to qter). Germline homozygosity (e.g. AA, BB alleles) at a given 
SNP results in calls at the 0 and 1 levels, respectively, germline heterozygosity (AB-
alleles) in calls around 0.5 (Y-Axis: 0-1). CNN-LOH in the tumor leads to loss of calls 
around 0.5 and to the presence of allelic imbalance calls derived from a sum of 
heterozygous normal cell (AB) and homozygous tumor cell (AA or BB) calls for a given 
locus resulting in values between 0-0.5 or 0.5-1 depending on the amount of cells 
carrying the aberration. Thus, in the areas when only contribution from one parent 
(LOH/CNN-LOH), two bands should we expected (0% and 100%->0 and 1.0. Y Axis). 
In the three cases (pFL7, pFL10, pFL14), the probes did not reach such thresholds 
because alterations are detected to be in mosaicism (not germline alterations). (C) 
Summary data of the FISH, CN, CNN-LOH, 1p36, TNFRSF14, EZH2 mutation, IGH 
clonality, BCL2 expression analyses and DLBCL component for the 18 pediatric FL 
patients. FISH was considered positive when splits in the BCL2, BCL6, MYC, IRF4 and 
IGH genes were detected; CN, when chromosomal imbalances were found by MIP-
assay or aCGH; 1p36, when CNN-LOH (detected by MIP-assay) or deletions (by MIP-
assay and/or aCGH) were observed at that region; TNFRSF14 and EZH2, when 
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mutations were found by direct sequencing; IGH clonality was positive when clonal IGH 
chain gene rearrangement was detected by PCR; BCL2 expression was positive when 
more than 25% of the cells were positive. In pFL2 only the region FR3 was evaluable in 
the IGH PCR reaction. In pFL18 IGH monoclonality was based on an analysis 
performed in an outside laboratory. CNN-LOH could not be determined in cases 1, 2, 
12, 16, 17, and 18.  
 
Figure 2: A-H: Histomorphological features of case pFL11 (FL3a) (A-D) without 
aberrant genotype and case pFL14 (FL3a) (E-H) with aberrant genotype: in both cases 
an infiltration of the lymphnode by enlarged abnormal follicles as well as remnants of 
normal reactive follicles (indicated by arrows) are seen in the low magnification (A,E, 
H&E x 25). The neoplastic follicles lack a clear starry sky pattern as well as the 
demarcation by a mantle zone (B,F, H&E x 100). The follicles consist of centroblasts 
and centrocytes (C,G, H&E x 1000). The lack of zonation is seen with 
immunohistochemistry for the proliferation marker Ki67 (D, H, Ki67 x 100), 
nevertheless a hot spot of proliferation can be observed in H. 
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I. Methods 
 
Determination of tumor content 
The tumor cell content was estimated by visual inspection on full slides of the respective 
lymphoma block used for the molecular analyses with help of the immunohistochemical stains 
for CD20 and at least one T-cell marker. Confusion with reactive B-cell-areas should not have 
caused significant wrong estimations as usually the lymphoma was more or less completely 
effacing the preexisting B-cell areas and as significant areas with small reactive follicles can be 
recognized cytologically even within the CD20-staining. 
 
The OncoScan FFPE Express assay copy number and somatic mutation determination 
DNAs from formalin-fixed paraffin-embedded material were hybridized on the MIP-assay using 
Oncoscan FFPE Express custom service (Affymetrix, Santa Clara, USA). Copy number 
determination of MIP-assay has been previously described.1 Briefly, MIP probes are 
oligonucleotides in which the two end sequences are complementary to two adjacent genomic 
sequences; these two ends anneal to the genomic DNA in an inverted fashion with a single 
base between them (generally the site of a single nucleotide polymorphism; SNP). In copy 
number analysis, genomic DNA is hybridized to the MIP probe and the reaction split into two 
separate tubes containing paired nucleotide mixes.2 Amplification and ligation allows 
circularization of the MIP probe. The probes are then amplified, labeled, detected and quantified 
by hybridization to tag microarrays. Gains and losses were defined by the use of a trial version 
of Nexus 6.0 beta Discovery Edition (Biodiscovery, El Segundo, USA) that integrates the 
genomic identification of significant targets in Cancer (GISTIC) algorithm for identifying 
significant regions of common genomic aberrations as well as the Allele specific Copy number 
Analysis of tumors (ASCAT) algorithm for addressing sample aneuploidy and mosaicism. The 
average resolution was of ~9 Kb/probe for whole genome backbone and ~3 Kb/probe for 
intragenic regions.  
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OncoScan FFPE Express also analyzes ~300 somatic mutations in relevant cancer genes. 
These files are generated from the raw CEL files as part of the primary data analysis process 
using Affymetrix software. Each sample has a score for each assay (each assay interrogates 
one previously described mutation). According to manufacturer’s instructions a score of 9 or 
higher indicates that an assay is a valid somatic mutation for that sample. According to this 
criterion, PIK3CA_pR88Q_c263G_A, FBXW7_pR278X_c832C_T, ABL1_pF359V_c1075T_G, 
NOTCH1_pL1586P_c4757T_C, PTEN_p_c165_minus_2A_C and PTEN_pQ110X_c328C_T 
mutations were found. No mutation detected by MIP assay was confirmed by Sanger 
sequencing.  
 
Array-CGH 
Microarray analysis has been performed using the Human Genome CGH Microarray 244A 
platform (Agilent Technologies, Santa Clara, USA). Experimental procedures were performed 
according to the manufacturer’s instructions. The array was scanned with the DNA microarray 
scanner (Agilent Technologies) at a resolution of 5µm/pixel. Signal intensities from the 
generated images were measured and evaluated with the Feature Extraction v10.7.3.1 and 
Agilent Genomic Workbench Standard Edition 6.5.0.58 software packages (Agilent 
Technologies). The average genome-wide resolution was of 0.65 Mb.   
 
Mutations 
Non-synonymous mutations were tested for their functional consequences in silico by using 
different aminoacid substitution prediction algorithms, including SIFT (Sorting Intolerant From 
Tolerant) and PolyPhen-2 (Polymorphism Phenotyping).  
 
Statistical analyses 
Statistical analyses were performed using PASW Statistics software version 18 (SPSS Inc., 
Chicago, USA). Chi-Square or Fisher´s exact tests were used to determine the significance of 
any differences between the clinical variables in samples with genomic aberrations vs. wild 
DOI: 10.3324/haematol.2012.073916
 5
type. Overall survival (OS) was defined as the time from diagnosis to date of most recent follow-
up. All statistical tests were considered significant at P≤0.05.  
 
Informed consent 
The study was performed in the framework of the BFM-NHL trial, for which central and local 
institutional review board approvals were obtained and according to the guidelines of the MMML 
Network Project of the Deutsche Krebshilfe (approved by the IRB of the Medical Faculty Kiel 
under 403/05). 
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Supplementary Table S1. Clinical, pathological and FISH data in pediatric FL 
ID Diag 2nd lymphoma component (%) 
Age, 
sex 
Tumor 
cells % Stage Loc 
BCL2 
exp^ 
Remnants 
of reactive 
B-follicles 
Marginal 
zone diff 
Treatment 
Protocol Outcome 
Follow-
up (m) 
BCL2/ 
t(14;18) BCL6 MYC IRF4 IGH 
Ref 
Oschlies 
et al3 
pFL1 FL3a - 8,m 70 II LN (c) no yes yes NHL-BFM 90 LFU in CR 114 wt wt na wt wt 4 
pFL2 FL3a FL 1 11,m 65 I LN (c) no yes yes NHL-BFM 90 LFU in CR 84 wt wt wt wt wt 6 
pFL3 FL3b DLBCL (90) & 15,m 65 III LN (ab), intestine 
yes 
(partial) yes no NHL-BFM 95 LFU in CR 156 wt wt na na split 10 
pFL4 FL3b DLBCL (50)$ 8,m 90 II T, LN (c) yes yes no NHL-BFM 90 LFU in CR 120 wt wt wt na split 13 
pFL5 FL3b - 10,f 95 III 
LN (c, ax, 
med, ab, 
ing) 
yes no no NHL-BFM 95 
Relapse  
DD second 
malignancy** 
112 wt split wt wt# split 16 
pFL6 FL3a FL 2 16,m 90 I LN (c) yes no no NHL-BFM 95 LFU in CR 17 wt wt wt wt na 18 
pFL7 FL3a - 17,m 80 I LN (c) yes (partial) no yes B-NHL BFM 04 Alive in CR 59 wt wt wt wt wt 21 
pFL8† FL3b DLBCL (30) 6,f 75 II LN (c) no no no Ritux + B-NHL BFM 04 Alive in CR 24 wt wt wt wt wt 23 
pFL9 FL3a FL2 15,f 75 I LN (c) yes yes no B-NHL BFM 04 Alive in CR 24 wt wt wt wt wt 25 
pFL10 FL3a - 6,m 70 na LN (femoral) yes na yes R-CHOP LFU in CR 36 wt wt wt wt
# wt - 
pFL11 FL3a - 10,m 75 II LN (c) yes (weak) yes yes B-NHL BFM 04  Alive in CR 19 wt wt wt wt wt - 
pFL12 FL2 - 17,f 80 na LN (c, med) yes no no na na na na na na na na - 
pFL13 FL3b - 6,f 20 I 
LN 
(retroauri
cular) 
yes yes (majority) no 
complete 
extirpation, w&w Alive in CR 11 wt wt wt wt wt - 
pFL14 FL3a FL1 and 2 18,m 80 I LN (ing) yes yes no complete extirpation, w&w Alive in CR 16 wt wt wt wt wt - 
pFL15 FL3a DLBCL (15) 9,f 90 III 
T, LN 
(c,ax,ab), 
liver, 
intestine 
yes yes (in tonsil) no NHL-BFM 95 LFU in CR 102 wt wt wt wt split 5 
pFL16 FL3b - 18,f 65 II LN (ing) na no no Ritux LFU in CR 39 wt wt wt wt# wt ‐ 
pFL17 FL3* - 9,m 50 na LN (c) na yes no na na na wt wt wt wt na - 
pFL18 FL2 - 18,m 80 I LN (c) na no no complete extirpation, w&w Alive in CR 36 wt wt wt wt wt - 
  Abbreviations: Diag, diagnosis; Loc, localization; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; m, male; f, female; LN, lymph nodes; diff, differentiation; DD, differential diagnosis; T, tonsil; c, cervical 
including nuchal and submental; ing, inguinal; med, mediastinal; ax, axillary; ab, abdominal; wt, wild type; na, not available; FU, follow-up; LFU, lost to follow-up; CR, complete remission; w&w, watch and wait; m, month; 
Ref, reference 
* Diagnosis as FL3a or FL3b was not available;  # Multiple IRF4 copies were detected by FISH; † The case pFL8 presents starry sky pattern- Burkitt like pattern; ** Nijmegen-breakage syndrome; differentiation between 
relapse and second malignancy not possible (no molecular genetics); another relapse DD second malignancy (no molecular genetics) 8 years after first lymphoma; alive; & The case pFL3 shows the diffuse growth in 90% 
of the biopsy as this is an infiltration of the intestinal wall. A secondary colonization of preexisting follicles of the Payer Plaques cannot be ruled out. Nevertheless, the histopathology nor an additional staining for FDC-
networks does not allow to differentiate in this case between secondary involvement and focal true follicular growth. $ The architecture and extension of the follicular component did not resemble secondary colonization of 
preexisting follicles; ^BCL2 expression data of ten cases were previously published by Oschlies et al, 20103  
 
I. Supplementary tables 
DOI: 10.3324/haematol.2012.073916
 7
 
Supplementary Table S2. Primer information for mutational analyses.  
Gene Primer Nucleotide sequence (5´-3´) PCR product (bp) 
TNFRSF14 TNFRSF14_ex1_F TCCTCTGCTGGAGTTCATCC 209 
 TNFRSF14_ex1_R CATGGGGAAGAGATCTGTGG  
 TNFRSF14_ex2_F ATCTCCCAATGCCTGTCCT 202 
 TNFRSF14_ex2_R AGAAGGGGGCAAGAGTGTCT  
 TNFRSF14_ex3_F TAGCTGGTGTCTCCCTGCTT 250 
 TNFRSF14_ex3_R GGCTGTGCTGGCCTCTTAC  
 TNFRSF14_ex4_F TCCACGTACCCCTCTCAGC 228 
 TNFRSF14_ex4_R GAAATGGGAGGGGTGTCC  
 TNFRSF14_ex5_F CCTCTGTCCGTCCCTCTCTT 218 
 TNFRSF14_ex5_R ACCTTCAAGCCTTTCTGCTG  
 TNFRSF14_ex6_F CTCCCTGAGGCTGAGTGAAC 277 
 TNFRSF14_ex6_R GGTGACAGAGCTCCAAGAGG  
 TNFRSF14_ex7_F CTGTGTCCCCTGATCAGACA 204 
 TNFRSF14_ex7_R CAGGACCCTCAGAGAACTGG  
 TNFRSF14_ex8_F AAAATGAACCCGAGAACCTG 267 
 TNFRSF14_ex8_R AGGTGGACAGCCTCTTTCAG  
ABL1 ABL1_F359V_F GCTGTACATGGCCACTCAGAT 224 
 ABL1_F359V_R GAGCCTAGTGTTTGCCTTTGTT  
NOTCH1 NOTCH1_L1586P_F ACCAGTACTGCAAGGACCACTT 220 
 NOTCH1_L1586P_R AAGACCACGTTGGTGTGCAG  
STK11 STK11_Q170X_F CCGCAGGTACTTCTGTCAGC 128 
 STK11_Q170X_R CCAGGTCGGAGATTTTGAGG  
PIK3CA PIK3CA_R88Q_F GCCTCCGTGAGGCTACATTA 233 
 PIK3CA_R88Q_R GAGGATCTTTTCTTCACGGTTG  
FBXW7 FBXW7_R278X_F ATAGAGCTGGAGTGGACCAGAG 212 
 FBXW7_R278X_R TGTTTAAAGGTGGTAGCTGTTGAG  
PTEN PTEN_p_c165_F AAATCTGTCTTTTGGTTTTTCTTG 274 
 PTEN_p_c165_R AATCGGTTTAGGAATACAATTCTG  
 PTEN_pQ110X_F TAACCCACCACAGCTAGAACTT 289 
 PTEN_pQ110X_R GAAACCCAAAATCTGTTTTCCA  
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Supplementary Table S3.  Genetic alterations of pediatric follicular lymphomas. 
ID No. CN alt/ CNN-LOH  CN gains CN losses CNN-LOH 
TNFRSF14 
status 
EZH2  
status 
Reference  
Oschlies et al.3  
pFL1 0 no no na wt wt 4 
pFL2 0 no no na wt wt 6 
pFL3 na na na na P16S c.1922 A>T  10 
pFL4 7 11q22.1-q25, 17q25.1-q25.3, Xpter-q28 
4, 6q11.1-qter, 17p13.3-q11.1, 
Xq28-qter no T272I/G232S wt 13 
pFL5 20 
1q21.1-q41, 2p16.2-p12, 3pter-
p14.2, 3q13.11-q13.32, 6pter-
p22.1, 13q21.1-qter, 18q12.3-qter, 
19q13.31-qter, Xq21.1-q22.2, 
Xq26.3-qter 
1pter-p12, 2q12.1-q22.3, 2q35-qter, 
3q13.32-q24, 6q11.1-qter,10p12.1-
p11.1, 10q24.32-qter,12q23.1-qter, 
13q11-q21.1, 18pter-q11.1 
no wt wt 16 
pFL6 0 no no no wt wt 18 
pFL7 1 no no 1p36.2-p34.1 S14C/ g.370T>C wt 21 
pFL8 5 10, 11q12.1-q23.3, 11q23.3 11q23.3-q25 17q12-q21.2 wt wt 23 
pFL9 0 no no no wt wt 25 
pFL10 3 6pter-p22.3, 7q31.1-q36.3 no 1pter-p36.13 g.370T>A wt - 
pFL11 0 no no no wt wt - 
pFL12 1 7 no na P9T wt - 
pFL13 0 no no no wt wt - 
pFL14 1 no no 1pter-p36.13 Q180X wt - 
pFL15 na nd nd na nd c.1922 A>T  5 
pFL16 1 6pter-p24.3 no na wt wt - 
pFL17 0 no no na V267M wt - 
pFL18 0 no no na wt wt - 
Abbreviations: CN alt, copy number alterations; CNN-LOH, copy number neutral loss of heterozygosity; nd, not done; na, not available; wt, wild type 
Notes: Regions in bold correspond to copy number gains of more than two copies /amplifications.  
The table does not include ''silent'' mutations or polymorphisms. 
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Supplementary Table S4. Whole copy number data of pediatric follicular lymphomas. 
Case CN status chr start end Size (Mb) 
ONCOSCAN  
pFL1  
no aberrations  
pFL2  
no aberrations    
pFL4  
High Gain 11q22.1-q25 99,634,634 134,324,142 34,69 
Gain 17q25.1-q25.3 69,229,399 78,723,423 9,49 
Gain Xpter-q28 0 146,983,016 146,93 
Loss Xq28-qter 146,983,017- 154,664,758 7,68 
Loss 4 0 191,273,063 191,27 
Loss 6q11.1-qter 61,941,918- 170,899,992 108,96 
Loss 17pter-q11.1 0 22,221,149 22,22 
pFL5  
High Gain 1q21.1-q41 143,599,182 215,218,824 71,62 
  Gain 2p16.2-p12 53,021,912 76,446,518 23,42 
  Gain 3pter-p14.2 0 61,085,250 61,09 
  Gain 3q13.11-q13.32 105,664,486 119,311,190 13,65 
  Gain 6pter-p22.1 0 29,392,572 29,39 
  Gain 13q21.1-qter 54,580,422 114,068,620 59,49 
  Gain 18q12.3-qter 40,314,818 76,117,153 35,80 
  Gain 19q13.31-qter 49,926,901 63,728,509 13,80 
  Gain Xq21.1-q22.2 81,184,537 102,751,070 21,57 
  Gain Xq26.3-qter 136,020,499 154,913,754 18,89 
  Loss 1pter-p12 0 119,845,934 119,85 
  Loss 2q12.1-q22.3 104,461,080 145,137,592 40,68 
  Loss 2q35-qter 218,893,446 242,634,600 23,74 
  Loss 3q13.32-q24 119,441,159 146,084,725 26,64 
  Loss 6q11.1-qter 61,871,980 170,821,724 108,95 
  Loss 10p12.1-p11.1 24,340,995 38,892,677 14,55 
  Loss 10q24.32 - qter 103,978,381 135,198,353 31,22 
  Loss 12q23.1 - qter 99,413,038 132,349,534 32,94 
  Loss 13q11-q21.1 18,069,540 54,580,422 36,51 
  Loss 18pter-q11.1 49,588 16,116,010 16,07 
pFL14  
CNN-LOH 1pter-p36.13 0 18,214,258 18,21 
ONCOSCAN/AGILENT244K 
pFL6  
no alterations  
pFL7  
CNN-LOH 1p36.32-p34.1 5,151,053 45,818,122 40,67 
pFL8  
Gain 10 0 135,374,737 135,37 
Gain 11q12.1-q23.3 58,686,057 117,196,931 58,51 
High Gain 11q23.3 117,207,811 118,931,293 1,72 
Loss 11q23.3-qter 118936,999 134,431,956 15,49 
CNN-LOH 17q21.31 - qter 40,729,078 78,774,742 38,05 
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Regions in bold correspond to copy number gains of more than two copies/ amplifications 
Numbering according to the Human Genome hg18/NCBI build 36.1 assembly 
CN: copy number; CNN-LOH, copy number neutral loss of heterozygosity 
 
 
 
 
 
 
 
 
 
 
 
 
pFL09  
no alterations  
pFL10  
High Gain 6pter-p22.3 0 20,530,644 20,53 
Gain 7q31.1-qter 113,399,531 158,717,957 45,32 
CNN-LOH 1pter-p36.13 0 17,582,810 17,58 
pFL11  
no alterations  
pFL12  
Gain 7 0 158,821,424 158,82 
pFL13  
no alterations  
 
AGILENT244K 
pFL16  
Gain 6pter-p24.3 181,550 9,878,354 9,7 
pFL17  
no alterations  
pFL18  
no alterations  
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Supplementary Table S5. TNFRSF14 mutational analysis of pediatric follicular lymphomas. 
Case Diagnosis 1p36 aberration Exon Position
& Ref nt Obs nt Mutation type Effect 
SIFT prediction 
(score*) 
Polyphen 
prediction 
pFL7 PedFL yes 
1 2486274 C G missense S14C tolerant (0.05) benign 
1 2486244 T C splice site - - - 
pFL10 PedFL yes 1 2486244 T A splice site - - - 
pFL14 PedFL yes 5 2482278 C T nonsense Q180X   
pFL3 PedFL no 1 2486269 C T missense P16S tolerant (0.34) probably damaging 
pFL4 PedFL no 
6 2481164 G A missense G232S tolerant (0.51) benign 
8 2479743 C T missense T272I tolerant (0.05) possibly damaging 
pFL12 PedFL no 1 2486290 C A missense P9T tolerant (0.6) benign 
pFL17 PedFL no 8 2479759 G A missense V267M tolerant (0.14) benign 
PedFL: pediatric follicular lymphoma SIFT: Sorting Intolerant From Tolerant predictor; nt: nucleotide 
*Treshold for intolerance is 0.05 
&Numbering according to the Human Genome hg18/NCBI build 36.1 
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Supplementary Figures 
 
Supplementary Figure S1. Global series included in the copy number analysis  
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Supplementary Figure S2. (A, B) Gain and amplification of 6p arm detected by MIP-assay in cases pFL5 and pFL10, respectively. A’ and B’ show FISH 
validation of the 6p25 gain/amplification, using an IRF4 break apart probe consisting in PAC-clone RP3-416J7 labeled in orange and BAC-clones RP5-
1077H22 and RP5-856G1 labeled in green. 
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Supplementary Figure S3. Comparison of chromosomal imbalances between pediatric FL and 
previously published pediatric FL positive for IRF4-translocation.4 
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